Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00487994 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,130
- Enrollment target
NCT00487994 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 2,130 participants.
The verdict
NCT00487994, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,130 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the overall safety of Lapaquistat Acetate, once daily (QD), by itself or in combination with atorvastatin in subjects with primary dyslipidemia.
Interventions
- DRUG Atorvastatin
- DRUG Lapaquistat acetate and atorvastatin
- DRUG Lapaquistat acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,130 participants |
| Start Date | 2004-11 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00487994
The ClinicalTrials.gov registry entry for NCT00487994 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Atorvastatin is the first listed.
NCT00487994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00487994 about?
NCT00487994 is a clinical study titled "Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia". The purpose of this study is to evaluate the overall safety of Lapaquistat Acetate, once daily (QD), by itself or in combination with atorvastatin in subjects with primary dyslipidemia.
What is the current status of trial NCT00487994?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,130 participants. The study started on 2004-11. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00487994?
The interventions under investigation include: Atorvastatin (DRUG), Lapaquistat acetate and atorvastatin (DRUG), Lapaquistat acetate (DRUG).
Who is sponsoring clinical trial NCT00487994?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.